BioCardia (BCDA)
(Delayed Data from NSDQ)
$2.98 USD
-0.14 (-4.49%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $2.90 -0.08 (-2.68%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
BioCardia, Inc. (BCDA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.00 | $25.00 | $25.00 | 738.93% |
Price Target
Only one analyst offered a short-term price target of $25.00 for BioCardia, Inc. This represents an increase of 738.93% from the last closing price of $2.98.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for BioCardia, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/26/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $25.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -1.19 |
BCDA FAQs
BioCardia, Inc. (BCDA) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for BioCardia, Inc. (BCDA) is $25.00. The current on short-term price targets is based on 1 reports.
The forecasts for BioCardia, Inc. (BCDA) range from a low of $25 to a high of $25. The average price target represents a increase of $738.93 from the last closing price of $2.98.
The current UPSIDE for BioCardia, Inc. (BCDA) is 738.93%
Only one analyst offered a short-term price target of $25.00 for BioCardia, Inc. This represents an increase of 738.93% from the last closing price of $2.98.